<code id='31F5EEEA98'></code><style id='31F5EEEA98'></style>
    • <acronym id='31F5EEEA98'></acronym>
      <center id='31F5EEEA98'><center id='31F5EEEA98'><tfoot id='31F5EEEA98'></tfoot></center><abbr id='31F5EEEA98'><dir id='31F5EEEA98'><tfoot id='31F5EEEA98'></tfoot><noframes id='31F5EEEA98'>

    • <optgroup id='31F5EEEA98'><strike id='31F5EEEA98'><sup id='31F5EEEA98'></sup></strike><code id='31F5EEEA98'></code></optgroup>
        1. <b id='31F5EEEA98'><label id='31F5EEEA98'><select id='31F5EEEA98'><dt id='31F5EEEA98'><span id='31F5EEEA98'></span></dt></select></label></b><u id='31F5EEEA98'></u>
          <i id='31F5EEEA98'><strike id='31F5EEEA98'><tt id='31F5EEEA98'><pre id='31F5EEEA98'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:focus    Page View:1155
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In